Avacta Group PLC Director/PDMR Shareholding (4617M)
28 July 2017 - 10:15PM
UK Regulatory
TIDMAVCT
RNS Number : 4617M
Avacta Group PLC
28 July 2017
28 July 2017
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Director/PDMR Shareholding
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and research reagents, announces that its Chief
Executive Officer, Dr Alastair Smith has today transferred 87,850
ordinary shares of 10p each ("Ordinary Shares") from his personal
holding to his self-invested personal pension (SIPP) at a price of
83.0p per Ordinary Share. Following this transaction, Dr Smith's
total interest in Ordinary Shares has remained unchanged.
Enquiries:
Avacta Group plc Tel: +44 (0)
Alastair Smith, Chief Executive 844 414 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0)
Geoff Nash / Giles Rolls - Nominated 207 220 0500
Adviser www.finncap.com
Tim Redfern / Alice Lane - Corporate
Broking
Tel: +44 (0)
WG Partners 203 705 9318
David Wilson Tel: +44 (0)
Nigel Barnes 203 705 9217
Claes Spang www.wgpartners.co.uk
Media Enquiries Tel: +44 (0)
FTI Consulting 203 727 1000
Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology and bleeding disorders as well as
partnered development programmes. Avacta is commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
The information communicated in this announcement is inside
information for the purposes of Article 7 of Regulation
596/2014.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial
responsibilities / person closely associated
------- ------------------------------------------------------------------------------------------------------------
a) Name Alastair Smith
------- ----------------------------------- -----------------------------------------------------------------------
2. Reason for the Notification
------- ------------------------------------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------- ----------------------------------- -----------------------------------------------------------------------
b) Initial notification/Amendment Initial notification
------- ----------------------------------- -----------------------------------------------------------------------
3. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
------- ------------------------------------------------------------------------------------------------------------
a) Name Avacta Group Plc
------- ----------------------------------- -----------------------------------------------------------------------
b) LEI n/a
------- ----------------------------------- -----------------------------------------------------------------------
4. Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
------- ------------------------------------------------------------------------------------------------------------
a) Description of Ordinary shares
the Financial of 10p
instrument, type
of instrument
-------
Identification GB00BYYW9G87
code
------- ----------------------------------- -----------------------------------------------------------------------
b) Nature of the Transfer of ordinary shares to SIPP via a sale and purchase.
transaction
------- ----------------------------------- -----------------------------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ---------------- --------------
83.0 pence 87,850
---------------- --------------
------- ----------------------------------- -----------------------------------------------------------------------
d) Aggregated information:
* Aggregated volume See above
* Price
------- ----------------------------------- -----------------------------------------------------------------------
e) Date of the transaction 28 July 2017
------- ----------------------------------- -----------------------------------------------------------------------
f) Place of the London Stock Exchange, AIM
transaction Market (XLON)
------- ----------------------------------- -----------------------------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHOKFDDBBKDQOB
(END) Dow Jones Newswires
July 28, 2017 08:15 ET (12:15 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Oct 2023 to Oct 2024